Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract Cancers

Gemcitabine-based chemotherapy is the current standard treatment for biliary tract cancers (BTCs) and resistance to gemcitabine remains the clinical challenge. TP53 mutation has been shown to be associated with poor clinicopathologic characteristics and survival in patients with BTCs, indicating tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Chiao-En, Pan, Yi-Ru, Yeh, Chun-Nan, Lunec, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690712/
https://www.ncbi.nlm.nih.gov/pubmed/33113997
http://dx.doi.org/10.3390/biom10111474

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690712/
https://www.ncbi.nlm.nih.gov/pubmed/33113997
http://dx.doi.org/10.3390/biom10111474

Ejemplares similares